NDC 70771-1833-01 - Sucralfate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70771-1833
- Requested NDC
- 70771-1833-01
- Package NDCs from labels
- 70771-1833-5, 70771-1833-3, 70771-1833-1, 70771-1833-01
- Manufacturer
- Zydus Lifesciences Limited
- Effective date
- 2026-08-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Sucralfate - Zydus Lifesciences Limited | Zydus Lifesciences Limited | 2026-08-08 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70771-1833-1 | Sucralfate | 100 in 1 BOTTLE | TABLET | 100 | 2 | |
| 70771-1833-3 | Sucralfate | 30 in 1 BOTTLE | TABLET | 30 | 2 | |
| 70771-1833-5 | Sucralfate | 500 in 1 BOTTLE | TABLET | 500 | 2 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70771-1833 | SUCRALFATE TABLET [ZYDUS LIFESCIENCES LIMITED] | 2 | Current NDC, 3 package rows | 20240310_882b7596-f62c-4be2-8f67-e64310718baa.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc. | 536b8c00-13ab-4397-a754-63a1c92bf883 | 2026-09-02 | Adverse reactions | 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | VistaPharm, LLC | cbfbe146-5d42-4a55-9050-df2b5581487a | 2026-09-02 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc. | 5ec71444-cc55-47bd-8abc-b3cfc3b47d8e | 2026-09-01 | Adverse reactions | 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | Chartwell RX, LLC | 37aee721-b9c7-4e6b-a1a1-e826d8541d6b | 2026-08-27 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Zydus Lifesciences Limited | 882b7596-f62c-4be2-8f67-e64310718baa | 2026-08-08 | Adverse reactions | ANDA215705 70771-1833-5 70771-1833-1 70771-1833-3 70771-1833 70771183301 314234 3f731a84-c141-4e26-ade3-39a9e4ea30e3 882b7596-f62c-4be2-8f67-e64310718baa XX73205DH5 |
| Sucralfate | SUCRALFATE | Viona Pharmaceuticals Inc | c708201b-2618-4470-a3ff-8ecf04d6b3a0 | 2026-08-08 | Adverse reactions | ANDA215705 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 444a743a-4843-4b33-bad5-3dfc1fb2d004 | 2026-07-29 | Adverse reactions | 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | Safecor Health, LLC | 526f6ebc-557c-4c53-8118-1907baa0820a | 2026-07-16 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 1eb38f64-4d5a-46e6-a030-057beece5e44 | 2026-07-10 | Adverse reactions | 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | Chartwell RX, LLC | 30c0965a-02a0-46b5-aa09-3f5fb5047b22 | 2026-07-06 | Adverse reactions | 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | NCS HealthCare of KY, LLC dba Vangard Labs | 3b0259fa-806f-44c1-8deb-c11dbd84582d | 2026-06-24 | Adverse reactions | ANDA215705 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | ASCLEMED USA INC. | cd25eb96-29ea-48b2-bdee-c2ea98f216b8 | 2026-05-18 | Adverse reactions | 314234 XX73205DH5 |
| Caldesene Baby | STARCH, CORN AND ZINC OXIDE | Insight Pharmaceuticals LLC | 9f12dee2-7afa-45e9-a729-0fd42bb77715 | 2026-04-22 | Warnings | O8232NY3SJ |
| Caldesene Medicated Protecting | CORNSTARCH AND ZINC OXIDE | Insight Pharmaceuticals LLC | ffc92a0f-a7cf-4a46-b2f1-089df2bbb96b | 2026-04-22 | Warnings | O8232NY3SJ |
| Sucralfate | SUCRALFATE | Safecor Health LLC | 1a6d96f2-fe1f-4aaf-8520-616973c224aa | 2026-04-07 | Adverse reactions | 314234 XX73205DH5 |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 92c8672a-c6b8-4ec8-a815-c30bdd960ac7 | 2026-03-30 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | PAI Holdings, LLC dba PAI Pharma | 113a068a-2ce9-421c-8b89-87ce30e19225 | 2026-03-11 | Warnings, Adverse reactions | XX73205DH5 |
| sucralfate | SUCRALFATE | Strides Pharma Science Limited | 8e25bff2-769e-4bd4-a6de-895c58b840d2 | 2026-03-10 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE ORAL SUSPENSION | Major Pharmaceuticals | 98a8fedd-fa06-416a-8a85-b899631978f9 | 2026-02-11 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc | a434bf8f-cc60-4d84-a9a4-61c3ff6b700e | 2026-01-21 | Adverse reactions | ANDA215705 314234 XX73205DH5 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.